What are the prospects for each of the three major segments of biopharmaceuticals?

Biopharmaceuticals refer to biologically activated preparations made from microorganisms, parasites, animal toxins, and biological tissues as starting materials, prepared by biological processes or separation and purification techniques, and controlled by biological techniques and analytical techniques to control the quality of intermediate products and finished products
.
According to different uses, biological drugs can be divided into three categories, namely genetic engineering drugs, biological vaccines and biological diagnostic reagents
.
So, what are the prospects for each of these three segments? The author makes a brief analysis in this article
.
What are the prospects of each of the three major segments of biological drugs? (Source: Pharmaceutical Network) Genetically engineered drugs Genetically engineered drugs refer to drugs produced by the application of genetic engineering technology
.
In recent years, with the vigorous development of genetic engineering technology, the global genetic engineering drug market has continued to expand
.
According to the "2020 China Gene Engineering Drug Project Business Plan" released by the Xinsijie Industry Research Center, in 2019, the global market size has exceeded 2 trillion yuan, and China's genetic engineering drug market share in the global market is relatively Small, the scale in the same year was only about 280 billion yuan, and the future market growth potential is huge
.
In the domestic market, with the emergence of the genetic engineering drug research and development boom and the improvement of the research and development capabilities of local pharmaceutical companies, many companies are actively making efforts or planning to deploy the genetic engineering drug field
.
For example, Anke Bio is vigorously expanding the genetic engineering drugs based on monoclonal antibody drugs, and the entire group industry is developing rapidly; Changchun Hi-Tech stated on the interactive platform in August 2021 that the company will focus on genetic engineering drugs, biological vaccines, and antibody drugs in the future.
, high-end chemical medicine and modern Chinese medicine five major sectors; ternary gene, which will be launched in January 2021, will also clearly increase the basic research and clinical application research of genetically engineered drugs
.
The industry pointed out that genetic engineering technology has opened a new era of innovative drug research and development, but at present there is no new drug developed by genetic engineering technology in the world.
, is expected to promote the accelerated implementation of innovative products
.
Biological vaccines Biological vaccines generally refer to vaccines at the molecular level prepared by biotechnology
.
In recent years, with the improvement of residents' living standards, vaccination awareness and health awareness have been continuously improved, which has led to the rapid development of China's biological vaccine industry
.
At present, China's innovative vaccines are basically second-class vaccines, which are self-funded vaccines.
Since the survival space of similar innovative vaccine products is much larger than that of foreign markets, a monopoly situation is less likely to occur, which has also attracted many vaccine companies to increase The research and development and sales of new second-class seedlings have made continuous progress in technology, production technology, original research innovation,
etc.
The industry believes that with the continuous expansion of residents' demand for vaccination, the internationalization of vaccine products, and the support of relevant favorable policies, China's biological vaccine industry has huge development potential and broad market prospects
.
According to CIC's calculations, driven by the second-class vaccine, the scale of China's vaccine market has grown from 24 billion yuan in 2016 to 64 billion yuan in 2020, with a compound growth rate of 20.
6% from 2016 to 2020.
It is expected that by 2022, The scale of China's vaccine market will reach 89 billion yuan
.
Biological diagnostic reagents Biological diagnostic reagents refer to diagnostic reagents prepared by the principles or methods of immunology, microbiology, molecular biology, etc.
, and used in vitro for the diagnosis, detection and epidemiological investigation of human diseases
.
According to the different general uses, it can be divided into two categories: in vivo diagnostic reagents and in vitro diagnostic reagents
.
Since 2020, China's in vitro diagnostic reagent market has developed very rapidly, the strength of domestic enterprises has been greatly improved, and the pace of domestic substitution has been further accelerated
.
Data shows that the market size of China's in vitro diagnostic reagents exceeded 90 billion yuan in 2019, and the market size in 2021 will exceed 100 billion yuan
.
With the continuous increase of capital, a series of favorable policies to support the development and growth of the industry, and the influx of high-level talents, the industry expects that China's in vitro diagnostic industry will usher in a blowout, and the future industrial development pattern will also show a situation where a hundred schools of thought contend, and innovative products will continue to emerge
.
Disclaimer: Under no circumstances does the information or opinions expressed in this article constitute investment advice to anyone
.